Gilead Sciences stock gains on options surge and dividend signal
Published on 09/14/2026 at 20:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences Inc. (ISIN US3755581036) stock traded up to USD 145.78 on the Nasdaq in a recent session in September 2026, reflecting a 1.4 percent intraday gain from the prior close and elevated options activity around the shares, according to MarketBeat on September 14, 2026.
Options volume and dividend drive interest
According to MarketBeat on September 14, 2026, call options on Gilead Sciences reached volumes that were roughly 54 percent above typical levels, highlighting heightened speculative and hedging activity around the stock.
The same analysis states that Gilead Sciences shares rose 1.4 percent to USD 145.78 during the referenced trading session, up USD 2.06 from a prior level of USD 143.72, which represents a short-term move that investors link to the options surge and upcoming cash returns to shareholders.
As Moomoo reported on September 13, 2026, Gilead Sciences will trade ex-dividend on September 15, 2026, with shareholders of record on that date set to receive a USD 0.82 per share dividend on September 29, 2026.
Recent revenue growth and cash generation
In its latest reported quarter, Gilead Sciences generated revenue of USD 7.80 billion, increasing 10.6 percent year over year, according to MarketBeat, which cited the company’s most recent quarterly results.
This double-digit revenue growth offers investors evidence that Gilead’s portfolio of antiviral and oncology therapies continues to expand its top line, with the 10.6 percent increase providing a concrete comparison against the prior-year quarter.
Gilead Sciences also declared a quarterly dividend of USD 0.82 per share in connection with those results, equivalent to an annualized payout of USD 3.28 per share and a dividend yield of about 2.2 percent at the reference price, as detailed by MarketBeat.
For investors focused on income, the combination of a USD 3.28 annualized dividend and revenue rising 10.6 percent year over year reinforces the stock’s profile as both a cash-return and growth vehicle within large-cap biopharmaceuticals.
Analyst sentiment and key risks
Analyst sentiment on Gilead Sciences remains broadly constructive, with the company carrying a consensus rating of Moderate Buy and an average price target of USD 158.78, implying around 10.5 percent upside from USD 143.72, according to data aggregated by MarketBeat as of September 11, 2026.
The same overview notes that Gilead Sciences entered 2026 at a share price of USD 122.74 and has since gained 17.1 percent to trade around USD 143.72, illustrating mid-teens year-to-date appreciation that aligns with the analyst view of moderate upside potential.
However, recent pipeline developments also underscore risk: Gilead’s TROP2-targeting antibody-drug conjugate sacituzumab govitecan, combined with pembrolizumab, did not meet the primary endpoint of statistical significance in a Phase III trial for first-line metastatic non-small cell lung cancer with high PD-L1 expression, as reported by VCBeatHealth on September 14, 2026.
This setback in a major oncology indication reminds investors that clinical trial outcomes can introduce volatility to Gilead Sciences stock, even as approved therapies and core antiviral franchises continue to drive revenue growth.
Market capitalization and trading range
Per Nasdaq-linked data summarized by MEXC on September 14, 2026, Gilead Sciences stock last traded at USD 145.99 on the Nasdaq, up 1.58 percent, or USD 2.27, from the prior closing price of USD 143.72.
The same snapshot reports a 52-week trading range from USD 108.46 to USD 157.29 for Gilead Sciences, placing the latest price of USD 145.99 in the upper portion of that band and roughly USD 37.53 above the 52-week low while still USD 11.30 below the 52-week high.
According to MEXC, Gilead Sciences carries a market capitalization of USD 178.21 billion as of September 14, 2026, with around 1.44 million shares traded in the latest regular session, which highlights substantial liquidity for institutional and retail investors.
Closing price and investor takeaway
Gilead Sciences stock closed at USD 143.72 on the Nasdaq on September 11, 2026, according to MarketBeat, and most recent intraday data show the shares trading at USD 145.99 as of September 14, 2026.
Gilead Sciences stock snapshot
- Company: Gilead Sciences Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: Nasdaq
- Price (as of September 14, 2026, 16:49): 145.99 USD
- Market capitalization: 178.21 billion USD (as of September 14, 2026)
- Sector / Industry: Biotechnology / Biological products
- Index membership: S&P 500
- Next earnings date: September 15, 2026
